×
Hero Background

Nonallergic Rhinitis Companies

ID: MRFR/Pharma/3701-HCR
110 Pages
Rahul Gotadki
October 2025

Nonallergic Rhinitis companies focus on developing solutions for individuals experiencing nasal inflammation unrelated to allergies. These companies contribute to the advancement of treatments that address the complexities of nonallergic rhinitis for improved patient comfort.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Nonallergic Rhinitis Market Research Report - Forecast till 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Nonallergic Rhinitis Market

Nonallergic Rhinitis Market

 


Latest Nonallergic Rhinitis Companies Updates:


November 2018: AstraZeneca sold its rights to the asthma drug Alvesco (ciclesonide) and nasal sprays Omnaris and Zetonna (ciclesonide) to Covis Pharma for USD 350 million. This move allowed AstraZeneca to focus resources on developing new medications for unmet needs.


October 2023: Glenmark Pharmaceuticals launched its nasal corticosteroid spray, Flixonase Nasal Spray (fluticasone propionate), in the Indian market for the treatment of nonallergic rhinitis. This launch provides a new treatment option for Indian patients suffering from the condition.


June 2023: Sanofi received FDA approval for its nasal corticosteroid spray, Dymista (fluticasone propionate and azelastine hydrochloride), for the treatment of nonallergic rhinitis in adults and adolescents aged 12 years and older. This approval expands Dymista's reach beyond its previous indication for allergic rhinitis.


List of Nonallergic Rhinitis Key companies in the market:



  • Pfizer Inc (U.S.)

  • Progenics Pharmaceuticals (U.S.)

  • GlaxoSmithKline (U.K.)

  • Sucampo Pharmaceuticals Inc (U.S.)

  • Ironwood Pharmaceuticals (U.S.)

  • Sanofi (France)

  • Salix Pharmaceuticals Ltd (U.S.)

  • Bayer (Germany)